KR920002625A - 말단에 3'-3' 또는 5'-5' 뉴클레오타이드간 결합을 갖는 올리고뉴클레오타이드 유사체 - Google Patents
말단에 3'-3' 또는 5'-5' 뉴클레오타이드간 결합을 갖는 올리고뉴클레오타이드 유사체 Download PDFInfo
- Publication number
- KR920002625A KR920002625A KR1019910011064A KR910011064A KR920002625A KR 920002625 A KR920002625 A KR 920002625A KR 1019910011064 A KR1019910011064 A KR 1019910011064A KR 910011064 A KR910011064 A KR 910011064A KR 920002625 A KR920002625 A KR 920002625A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- radical
- oligonucleotides
- oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R15/00—Details of measuring arrangements of the types provided for in groups G01R17/00 - G01R29/00, G01R33/00 - G01R33/26 or G01R35/00
- G01R15/14—Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks
- G01R15/18—Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks using inductive devices, e.g. transformers
- G01R15/186—Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks using inductive devices, e.g. transformers using current transformers with a core consisting of two or more parts, e.g. clamp-on type
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 SV40TS17, SV40TS17 및 SV40TAS17(3'-3',5'-5')을 서열분석한 방사선 사진이다.
제2도는 신선한 사람 혈청으로 dT20및 dT20(3'-3',5'-5')를 절단시킨 방사선 사진이다.
제3도는 SVpdE 절단에 대한 방사선 사진이다.
Claims (8)
- 일반식(Ⅰ) 또는 (Ⅱ)의 올리고뉴클레오타이드 및 이의 생리학적으로 허용되는 염.상기식에서 R1은 수소 또는 일반식(Ⅲ)의 라디칼이고,R2은 수소 또는 일반식(Ⅳ)의 라디칼이며,단 R1또는 R2의 라디칼 중 하나 이상은 일반식(Ⅲ) 또는 (Ⅳ)의 라디칼이고, B는 염기, 예를 들어 천연 염기〔예 : 아데닌, 티민, 시토신, 구아닌〕또는 비천연 염기〔예 : 퓨린, 2,6-디아미노 퓨린, 7-데아자아데닌, 7-데아자구아닌 또는 N4,N4-에테노시토신〕, 또는 이의 프로드럭(prodrug)형태이며, W 및 W'는 서로 독립적으로 산소 또는 황이고, Z 및 Z'는 서로 독립적으로 O~;S~;C1-C18-알콕시, 바람직하게는 C1-C18-알콕시, 특히 바람직하게는 C1-C3-알콕시, 특히 메톡시; C1-C8바람직하게는 C1-C8-알킬, 특히 바람직하게는 C1-C3-알킬 특히 메틸 NHR3(여기에서 R3는 바람직하게는 C1-C18-알킬, 특히 바람직하게는 C1-C18-알킬, 특히 C1-C4-알킬, 또는 C1-C4-알콕시-C1-C6-알킬, 바람직하게는 메톡시에틸; NR3R4(여기에서 R3는 상기 정의한 바와 같고, R4는 바람직하게는 C1-C18-알킬, 특히 바람직하게는 C1-C18-알킬, 특히 C1-C4-알킬이거나, R3와 R4는 질소원자와 함께 O,S,N으로 부터의 또다른 헤테로원자를 추가로 함유할 수 있는 5 또는 6원 헤테로사이클릭 환(예 : 모르폴린)을 형성한다)이며, Y는 O-Si(R2), OCH2, C(O)NR 또는 O-CH2-C(O) (여기에서, R은 C1-C6-알킬, 아릴 또는 C5- 또는 C6-사이클로알킬이다)이고, n은 5 내지 60, 바람직하게는 10 내지 40, 특히 바람직하게는 15 내지 25의 정수이다.
- 제1항에 있어서, R2가 일반식(Ⅳ)의 라디칼이고 R1이 수소이거나, R1및 R2가 각각 일반식(Ⅲ) 및 (Ⅳ)의 라디칼이거나 R2가 수소이고, R1이 일반식(Ⅲ)의 라디칼(여기에서 W또는 Z는 산소가 아니다)인 일반식(Ⅰ)의 올리고뉴클레오타이드.
- 제1항 또는 2항에 있어서, W가 산소이거나 Z와 W가 모두 산소인 일반식(Ⅰ)의 올리고뉴클레오타이드.
- 제1항 또는 3항중 어느 한 항에 있어서, R2가 일반식(Ⅳ)의 라디칼이고, R1이 수소인 일반식(Ⅰ)의 올리고뉴클레오타이드.
- 제1항 내지 4항중 어느 한항에 있어서, 세포내 흡수가 유리하고 시험관내 또는 생체내에서 리포터 그룹으로 작용하는 그룹, 및/또는 올리고뉴클레오타이드가 생물학적 DNA 또는 RNA와 하이브리드화되는 경우 이 DNA 또는 RNA 분자를 공격하는 그룹에 의해 치환되어 결합을 형성하거나 절단하는 올리고뉴클레오타이드.
- (a)3'- 또는 5'- 말단 인(Ⅲ) 또는 인(Ⅴ) 그룹을 갖는 뉴클레오타이드 단위 또는 이의 활성화된 유도체를 유리된 3'- 또는 5'- 말단 하이드록실 그룹을 갖는 또다른 뉴클레오타이드 단위와 반응시키거나 (b)동일한 방법으로 올리고뉴클레오타이드를 단편으로 합성하고, 경우에 따라, 다른 작용물을 보호하기 위하여 (a)또는 (b)에서와 같이 수득된 올리고뉴클레이타이드에 일시적으로 도입된 보호그룹 하나 이상을 제거시키며, 경우에 따라, 이러한 방법으로 수득된 일반식(Ⅰ)의 올리고뉴클레오타이드를 이들의 생리학적으로 허용되는 염으로 전환시킴을 특징으로 하여, 제1항 내지 5항에 따른 일반식(Ⅰ)의 올리고뉴클레오타이드를 제조하는 방법.
- 제1항 내지 5항중 어느 한항에 있어서, 이본쇄 또는 일본쇄 핵산에 대한 결합에 기초하는 화학적 하이브리드화 방법, 핵산의 생물학적 작용의 조절 또는 억제, 및 바이러스 게놈 작용물의 발현의 선별적 억제 및 바이러스 질환의 예방 및 치료, 온코진(oncogene)작용의 억제 및 암 치료에 사용하기 위한 일반식(Ⅰ) 또는 (Ⅱ)의 올리고뉴클레오타이드.
- 제1항 내지 5항에 따른 화합물 하나 이상을 경우에 따라 바람직하게는 정맥내 투여 또는 국소투여용의 생리학적으로 허용되는 보조제 및/또는 비이클을 함께 함유하는 약제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4021019.7 | 1990-07-02 | ||
DE4021019 | 1990-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920002625A true KR920002625A (ko) | 1992-02-28 |
KR100200400B1 KR100200400B1 (ko) | 1999-06-15 |
Family
ID=6409497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910011064A KR100200400B1 (ko) | 1990-07-02 | 1991-07-01 | 말단에 3'-3' 또는 5'-5' 뉴클레오타이드간 결합을 갖는 올리고뉴클레오타이드유사체 및 이의 제조 방법 |
Country Status (22)
Country | Link |
---|---|
US (1) | US5750669A (ko) |
EP (1) | EP0464638B1 (ko) |
JP (1) | JP3186795B2 (ko) |
KR (1) | KR100200400B1 (ko) |
AT (1) | ATE151076T1 (ko) |
AU (1) | AU647143B2 (ko) |
CA (1) | CA2045891C (ko) |
CZ (1) | CZ285408B6 (ko) |
DE (1) | DE59108644D1 (ko) |
DK (1) | DK0464638T3 (ko) |
ES (1) | ES2099718T3 (ko) |
FI (1) | FI104177B (ko) |
GR (1) | GR3023432T3 (ko) |
HU (1) | HU215147B (ko) |
IE (1) | IE912309A1 (ko) |
IL (1) | IL98672A (ko) |
NO (1) | NO303018B1 (ko) |
NZ (1) | NZ238769A (ko) |
PT (1) | PT98169B (ko) |
SK (1) | SK279544B6 (ko) |
TW (1) | TW206232B (ko) |
ZA (1) | ZA915056B (ko) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
ES2103408T3 (es) * | 1992-09-24 | 1997-09-16 | Hoechst Ag | Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente. |
WO1994022891A1 (en) * | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
US6605708B1 (en) | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
CN1060177C (zh) * | 1997-06-28 | 2001-01-03 | 中国科学院上海生物化学研究所 | 3′-单磷酸化寡核苷酸 |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
DE19935756A1 (de) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
US6271360B1 (en) | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
EP1702983A3 (en) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
US20040215010A1 (en) * | 2000-06-13 | 2004-10-28 | Viktor Kumarev | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use |
WO2002026757A2 (en) * | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
GB0114007D0 (en) * | 2001-06-08 | 2001-08-01 | Isis Innovation | Oilgonucleotides |
US7070933B2 (en) * | 2001-09-28 | 2006-07-04 | Gen-Probe Incorporated | Inversion probes |
CA2471967A1 (en) * | 2002-01-03 | 2003-07-31 | Board Of Regents, The University Of Texas System | Wt1 antisense oligos for the inhibition of breast cancer |
US7741297B2 (en) * | 2002-02-04 | 2010-06-22 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
AU2005252662B2 (en) * | 2004-06-03 | 2011-08-18 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
CA2679750A1 (en) | 2008-09-23 | 2010-03-23 | Nexus Dx, Inc. | Methods for detecting nucleic acids in a sample |
EP2781523A1 (en) | 2013-03-18 | 2014-09-24 | Miltenyi Biotec GmbH | Lipophilic oligonucleotide analogs |
KR101323476B1 (ko) * | 2013-06-12 | 2013-10-31 | 조선미 | 건물용 층간소음 방지재와 이를 이용한 층간소음 방지구조 및 그 시공 방법 |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
CA3020343A1 (en) * | 2016-04-08 | 2017-10-12 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
CN111050806A (zh) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
BR112020020670A2 (pt) * | 2018-04-12 | 2021-03-02 | Wave Life Sciences Ltd. | composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4123610A (en) * | 1977-03-09 | 1978-10-31 | The United States Government | Nucleic acid crosslinking agent and affinity inactivation of nucleic acids therewith |
US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
FR2540122B1 (fr) * | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
DE3332068A1 (de) * | 1983-09-06 | 1985-03-21 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von nukleosidalkyl-, aralkyl- und arylphosphoniten und -phosphonaten |
US4795700A (en) * | 1985-01-25 | 1989-01-03 | California Institute Of Technology | Nucleic acid probes and methods of using same |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
JPH03503894A (ja) * | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド n‐アルキルホスホラミデート |
WO1990012022A1 (en) * | 1989-03-31 | 1990-10-18 | University Patents, Inc. | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections |
-
1991
- 1991-06-26 DK DK91110570.8T patent/DK0464638T3/da active
- 1991-06-26 DE DE59108644T patent/DE59108644D1/de not_active Expired - Lifetime
- 1991-06-26 EP EP91110570A patent/EP0464638B1/de not_active Expired - Lifetime
- 1991-06-26 AT AT91110570T patent/ATE151076T1/de not_active IP Right Cessation
- 1991-06-26 ES ES91110570T patent/ES2099718T3/es not_active Expired - Lifetime
- 1991-06-28 CA CA002045891A patent/CA2045891C/en not_active Expired - Lifetime
- 1991-06-28 NZ NZ238769A patent/NZ238769A/en not_active IP Right Cessation
- 1991-06-28 FI FI913169A patent/FI104177B/fi not_active IP Right Cessation
- 1991-06-30 IL IL9867291A patent/IL98672A/en not_active IP Right Cessation
- 1991-07-01 CZ CS912014A patent/CZ285408B6/cs not_active IP Right Cessation
- 1991-07-01 PT PT98169A patent/PT98169B/pt not_active IP Right Cessation
- 1991-07-01 AU AU79475/91A patent/AU647143B2/en not_active Expired
- 1991-07-01 SK SK2014-91A patent/SK279544B6/sk not_active IP Right Cessation
- 1991-07-01 KR KR1019910011064A patent/KR100200400B1/ko not_active IP Right Cessation
- 1991-07-01 ZA ZA915056A patent/ZA915056B/xx unknown
- 1991-07-01 HU HU215/91A patent/HU215147B/hu unknown
- 1991-07-01 IE IE230991A patent/IE912309A1/en not_active IP Right Cessation
- 1991-07-01 NO NO912585A patent/NO303018B1/no not_active IP Right Cessation
- 1991-07-02 JP JP18820291A patent/JP3186795B2/ja not_active Expired - Lifetime
- 1991-07-27 TW TW080105851A patent/TW206232B/zh not_active IP Right Cessation
-
1994
- 1994-08-01 US US08/282,503 patent/US5750669A/en not_active Expired - Lifetime
-
1997
- 1997-05-15 GR GR970401081T patent/GR3023432T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920002625A (ko) | 말단에 3'-3' 또는 5'-5' 뉴클레오타이드간 결합을 갖는 올리고뉴클레오타이드 유사체 | |
US5955599A (en) | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages | |
Lesnikowski et al. | Octa (thymidine methanephosphonates) of partially defined stereochemistry: synthesis and effect of chirality at phosphorus on binding to pentadecadeoxyriboadenylic acid | |
RU2227143C2 (ru) | Новые бициклонуклеозидные аналоги | |
US5596091A (en) | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides | |
EP0552766B1 (de) | Oligonucleotidanaloga, deren Herstellung und Verwendung | |
US5532130A (en) | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides | |
ES2244957T3 (es) | Oligonucleotidos modificados, su preparacion, asi como su empleo. | |
CA2069905A1 (en) | Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates | |
JP3653102B2 (ja) | 末端3′−3′および/または5′−5′連鎖を有するオリゴリボヌクレオチドおよびリボザイム類縁体 | |
JP7138349B2 (ja) | 核酸化合物およびオリゴヌクレオチド | |
KR100273824B1 (ko) | 비뉴클레오티드성 그룹을 갖는 3'-유도된 올리고뉴클레오티드 동족체, 이의 제조방법 및 이를 함유하는 약제학적 제제 | |
JP2005525991A5 (ko) | ||
JP4789095B2 (ja) | ウイルムス腫瘍遺伝子(wt1)に対する発現阻害物質を含んで成る固形腫瘍治療剤 | |
US5936077A (en) | Solid phase synthesis of oligonucleotides | |
US5955600A (en) | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
Pieles et al. | Preparation of a novel psoralen containing deoxyadenosine building block for the facile solid phase synthesis of psoralen-modified oligonucleotides for a sequence specific crosslink to a given target sequence | |
JP2000512630A (ja) | 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 | |
US8247540B2 (en) | Caged nucleotides and oligonucleotides and their application | |
WO1990012022A1 (en) | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections | |
JP3904260B2 (ja) | ウイルムス腫瘍遺伝子(wt1)に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤 | |
DE59906041D1 (de) | Glycerylnucleotide, verfahren zu ihrer herstellung und ihre verwendung | |
JPH069682A (ja) | レトロウイルス感染用治療薬としてのポリヌクレオチドホスホロジチオエート | |
KR930702374A (ko) | 안티 센스 핵산 유도체 | |
Allart et al. | 1, 5-Anhydro-2-deoxy-D-altritol oligonucleotides as conformationally restricted analogues of RNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110210 Year of fee payment: 13 |
|
EXPY | Expiration of term |